Saturday 17 October 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024. In the quarter to June 2026, revenue grew 19.6%, EPS grew 65.2%, free cash flow grew 26.7% and total debt rose 2.40%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.28
0.52
−5.91%
Follow SGHT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.54 | 2.56 | 5.35 | 2.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(52.17) | (28.93) | (226.35) | (20.67) | |
P/B ratio |
5.59 | 3.77 | 6.47 | 2.80 | |
Price to Tangible BV |
5.59 | 3.77 | 6.47 | 2.80 | |
EV/Sales |
3.08 | 2.00 | 4.71 | 1.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.04) | (6.33) | (12.26) | (4.15) | |
EV/FCF |
(10.99) | (6.26) | (12.11) | (4.08) | |
Quick Ratio |
4.45 | 5.26 | 9.22 | 8.63 | |
Current Ratio |
4.95 | 5.86 | 10.22 | 9.60 | |
Net Debt/EBITDA |
10.98 | 3.68 | 15.52 | 6.93 | |
Debt/Assets |
38.88% | 36.95% | 34.95% | 34.47% | |
Debt/Equity |
0.77 | 0.75 | 0.63 | 0.62 | |
Asset Turnover |
0.74 | 0.66 | 0.60 | 0.59 | |
Operating CF/Net income |
1.27 | 0.54 | 0.44 | 1.07 | |
Capex/Depreciation |
(0.06) | (0.18) | 0.46 | (0.48) | |
Interest Coverage |
(3.01) | (9.79) | (2.85) | (6.05) | |
Research and Development Expense of Revenue |
10.74% | 12.93% | 11.95% | 16.84% | |
Selling, General and Administrative Expense of Revenue |
97.27% | 136.28% | 93.30% | 109.26% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.67% | 14.48% | 12.50% | 12.16% | |
Graham Net Nets |
0.17 | 0.25 | 0.15 | 0.34 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.33%) | (18.83%) | (9.46%) | (26.16%) | |
Free Cash Flow Yield |
(7.90%) | (12.49%) | (7.27%) | (17.70%) | |
Revenue per Share |
0.43 | 0.37 | 0.39 | 0.38 | |
Operating CF per Share |
(0.10) | (0.13) | (0.03) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.13) | (0.03) | (0.17) | |
Cash per Share |
1.46 | 1.58 | 1.76 | 1.76 | |
Shareholders Equity per Share |
0.97 | 1.00 | 1.23 | 1.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.00 | 1.23 | 1.23 | |
Free Cash Flow |
(5.68) | (7.09) | (1.67) | (8.89) | |
Working Capital |
80.94 | 88.35 | 101.71 | 101.76 | |
Capital Expenditures |
(0.02) | (0.06) | 0.16 | (0.17) | |
Net Current Asset Value |
49.46 | 50.71 | 61.38 | 61.63 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | (0.01) | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.50 | 10.01 | 10.27 | 11.34 | |
Average Payables |
1.99 | 2.13 | 1.52 | 1.52 | |
Average Inventory |
5.95 | 6.41 | 7.05 | 7.04 | |
Average Assets |
113.42 | 119.69 | 129.07 | 129.93 | |
Average Common Equity |
61.45 | 65.77 | 75.73 | 79.62 |
Columns are period end dates